First Tracks Biotherapeutics annual return on equity
2024
First Tracks Biotherapeutics Return on Equity (ROE) Growth & History (TRAX)
First Tracks Biotherapeutics's return on equity was −40.85% for fiscal 2024.
View full First Tracks Biotherapeutics company overviewFirst Tracks Biotherapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −40.85% | — |
First Tracks Biotherapeutics quarterly return on equity
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | −15.66% | — |
First Tracks Biotherapeutics return on equity trends
The latest reported quarter, Q2 2026 · Jun 30, shows −15.66%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review First Tracks Biotherapeutics source filings ↗